EZH2 is an important epigenetic regulator, but its role in diffuse large B-cell lymphoma (DLBCL) pathogenesis and its relationship with MYC, BCL2, and TP53 expression, chromosomal rearrangements, and clinical features are still poorly understood. So, we investigated EZH2 expression and its associations with the immunophenotypic presentations, including MYC, BCL2, and TP53 expression, MYC, BCL2, and BCL6 translocation status, clinicopathological features, and therapeutic response to R-CHOP in a series of 139 DLBCL cases. EZH2 positivity was associated with MYC and TP53 expression (p = 0.0002 and p = 0.0000, respectively) and to high proliferative index (Ki67>70%, p = 0.0082). No associations were found among EZH2 expression and chromosomal translocation status. The non-germinal center (nGC) DLBCL presented most of associations observed in the general sample; however, only TP53 immunodetection showed associations with EZH2 expression in the germinal center (GC) DLBCL. EZH2 expression had no impact on therapeutic efficacy in R-CHOP-treated patients. In conclusion, EZH2 seems to be upregulated by MYC, to rely on TP53 alterations, and is associated with high proliferative tumors in DLBCL, which might be dependent on GC or nGC subclassifications. Furthermore, it is not a therapeutic efficacy marker to R-CHOP in our series.

中文翻译：

---

EZH2表达取决于弥漫性大B细胞淋巴瘤中MYC和TP53的调控。

EZH2是重要的表观遗传调控因子，但在弥漫性大B细胞淋巴瘤（DLBCL）发病机理中的作用及其与MYC，BCL2和TP53表达，染色体重排以及临床特征的关系仍然知之甚少。因此，我们在139例DLBCL病例中调查了EZH2表达及其与免疫表型的关系，包括MYC，BCL2和TP53表达，MYC，BCL2和BCL6易位状态，临床病理特征以及对R-CHOP的治疗反应。EZH2阳性与MYC和TP53表达（分别为p = 0.0002和p​​ = 0.0000）和高增殖指数（Ki67> 70％，p = 0.0082）相关。在EZH2表达与染色体易位状态之间未发现关联。非生发中心（nGC）DLBCL呈现了在一般样本中观察到的大多数关联。然而，只有TP53免疫检测显示与生发中心（GC）DLBCL中的EZH2表达相关。EZH2表达对R-CHOP治疗的患者的疗效没有影响。总之，EZH2似乎被MYC上调，依赖于TP53的改变，并且与DLBCL中的高增殖性肿瘤有关，这可能取决于GC或nGC的亚型。此外，它不是我们系列中R-CHOP的治疗功效标志物。并与DLBCL中的高增殖性肿瘤有关，这可能取决于GC或nGC的亚分类。此外，它不是我们系列中R-CHOP的治疗功效标志物。并与DLBCL中的高增殖性肿瘤有关，这可能取决于GC或nGC的亚分类。此外，它不是我们系列中R-CHOP的治疗功效标志物。